173 related articles for article (PubMed ID: 8102640)
21. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
22. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
[TBL] [Abstract][Full Text] [Related]
23. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations.
Yeager AM; Rowley SD; Kaizer H; Santos GW
Am J Pediatr Hematol Oncol; 1990; 12(3):245-56. PubMed ID: 2240470
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Gluckman E; Esperou-Bourdeau H; Reiffers J; Pico JL; Bordigoni P; Thuret I; Blaise D; Bernaudin F; Jouet JP
J Clin Oncol; 1994 Jun; 12(6):1217-22. PubMed ID: 8201385
[TBL] [Abstract][Full Text] [Related]
27. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
[TBL] [Abstract][Full Text] [Related]
28. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
29. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P
Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857
[TBL] [Abstract][Full Text] [Related]
30. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
31. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
[TBL] [Abstract][Full Text] [Related]
32. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
34. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
35. The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
Wang C; Qiao Z; Yang L; Ma L; Zhang H; Zhang J
Chin Med J (Engl); 1996 Apr; 109(4):304-7. PubMed ID: 8758293
[TBL] [Abstract][Full Text] [Related]
36. Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia.
Min YH; Lee ST; Kim JS; Jang JH; Suh HC; Kim HO; Hahn JS; Ko YW
Yonsei Med J; 2001 Feb; 42(1):65-73. PubMed ID: 11293503
[TBL] [Abstract][Full Text] [Related]
37. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Gutierrez-Aguirre CH; Cantú-Rodríguez OG; Gonzalez-Llano O; Salazar-Riojas R; Martinez-González O; Jaime-Pérez JC; Morales-Toquero A; Tarín-Arzaga LC; Ruiz-Argüelles GJ; Gómez-Almaguer D
Hematology; 2007 Jun; 12(3):193-7. PubMed ID: 17558694
[TBL] [Abstract][Full Text] [Related]
38. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
39. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
40. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission.
Petersen FB; Lynch MH; Clift RA; Appelbaum FR; Sanders JE; Bensinger WI; Benyunes MC; Doney K; Fefer A; Martin P
J Clin Oncol; 1993 Jul; 11(7):1353-60. PubMed ID: 8315433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
